(Q34411560)

2 August 2017

title

PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. (English)

1 reference

2 August 2017

0 references

Yan Q Chen

1

1 reference

2 August 2017

Jason S Troutt

series ordinal

2

1 reference

2 August 2017

Robert J Konrad

series ordinal

3

1 reference

2 August 2017

publication date

1 May 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

49

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

445-455

1 reference

2 August 2017

1 reference

12 December 2020

Molecular biology of PCSK9: its role in LDL metabolism

1 reference

12 December 2020

LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor

1 reference

12 December 2020

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

1 reference

12 December 2020

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans

1 reference

12 December 2020

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

1 reference

12 December 2020

Apolipoprotein E receptor 2 is involved in neuritic plaque formation in APP sw mice.

1 reference

12 December 2020

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

1 reference

12 December 2020

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

1 reference

12 December 2020

PCSK9: a promising therapeutic target for dyslipidemias?

1 reference

12 December 2020

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

1 reference

12 December 2020

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

1 reference

12 December 2020

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

1 reference

12 December 2020

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

1 reference

12 December 2020

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

12 December 2020

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

1 reference

12 December 2020

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

1 reference

12 December 2020

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

1 reference

12 December 2020

Reciprocal regulation of very low density lipoprotein receptors (VLDLRs) in neurons by brain-derived neurotrophic factor (BDNF) and Reelin: involvement of the E3 ligase Mylip/Idol

1 reference

12 December 2020

Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment

1 reference

12 December 2020

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

1 reference

12 December 2020

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

1 reference

12 December 2020

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

1 reference

12 December 2020

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

1 reference

12 December 2020

The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1.

1 reference

12 December 2020

Cholesterol metabolism in the brain

1 reference

12 December 2020

The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.

1 reference

12 December 2020

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

1 reference

12 December 2020

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

12 December 2020

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

1 reference

12 December 2020

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

1 reference

12 December 2020

Circadian variation of postprandial lipemia.

1 reference

12 December 2020

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

1 reference

12 December 2020

The role of apolipoprotein E in Alzheimer's disease

1 reference

12 December 2020

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia

1 reference

12 December 2020

Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease

1 reference

12 December 2020

Genetic and metabolic determinants of plasma PCSK9 levels

1 reference

12 December 2020

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

1 reference

12 December 2020

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

1 reference

12 December 2020

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity

1 reference

12 December 2020

Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain

1 reference

12 December 2020

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

1 reference

12 December 2020

Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system

1 reference

12 December 2020

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

1 reference

12 December 2020

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

1 reference

12 December 2020

Low diurnal variability of apolipoprotein A1, apolipoprotein B and apolipoprotein B/apolipoprotein A1 ratio during normal sleep and after an acute shift of sleep

1 reference

12 December 2020

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

1 reference

12 December 2020

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

1 reference

12 December 2020

A new method for measurement of total plasma PCSK9: clinical applications

1 reference

12 December 2020

10.1007/S11745-014-3895-6

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1025857438

0 references

1 reference